Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's going to be tough. The AML data coming out soon is for the Active arm patients who are the sickest of the sick, so I don't expect any CR's with them (I hope I'm wrong).
Maybe next year we will get some CR's in the Adjuvant arm patients, but from what I understand, the adjuvant patients will have to be monitored for a much longer time period.
I hope it doesn't happen, but I have kind of resigned myself to a reverse split in the next month.
If it happens, the new higher price will start to drop down (as normal) and then I will just buy more shares.
Lincoln Park Capital Fund has agreed not to cause or engage in any direct or indirect short selling or hedging of Marker's common stock. No warrants are being issued in this transaction, and the Agreement does not contain any rights of first refusal, participation rights, penalties or liquidated damages provisions in favor of any party.
At least that's a positive on top of the positive of the needed cash.
Next comes the negative reverse split.
Not exactly sure what tremtelectogene empogeditemcel or "trem-cel" is. It sounds like from the study that the patient took the CD33-targeted therapy Mylotarg which is made by Pfizer, so I don't know how much of a role that the Vor Biopharma therapy had in the CR.
Whatever "trem-cel" is, is seems to be genitically engineered, so #1 like Car-T which is also genitically engineered, it is probably much more expensive that MRKR Multi-TAA, and #2 being genitically engineered, don't know what side effects will be in larger studies, like cytokine release syndrome.
Not sure if MRKR will have any CR's in the upcoming data as that will be for the Active arm patients who are the sickest of the sick.
Maybe next year we will get some CR's in the Adjuvant arm patients (we hope) (both patients and investors).
The only thing MRKR can announce about ASH ... is that is what their stock price turned in to.
Thank You, so they have 2 months to report GREAT data news. Hate to say it but I kind of doubt it.
Question. When exactly is the last date we have to be above $1? Or, to put it another way, when is the date we have to do a reverse split by?
I have been putting $ aside all year waiting for the RS. Once it happens, the new RS price will start to drop.
THEN IT IS BUY TIME. Or, to put it another way.
THEN IT IS POSSIBLY WASTE MORE MONEY TIME.
Either way, I will stay on the ship while it still floats ... or I will go down with it.
Good Luck to patients and investors.
I just read this (was not home), but a belated Thank You.
Phantom ? ......
“Interim results from the TACTOPS study PRESENTED at ASCO in 2020" ... that was MT-401, not MT-601.
"Marker intends to initiate a multicenter Phase 1 trial for the treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with front-line chemotherapy in 2023." ........ QUESTION?
Was the Baylor TACTOPS study also done with "in combination with front-line chemotherapy"?
I don't think so, https://clinicaltrials.gov/ct2/show/NCT03192462, "or patients who are not eligible for or have elected not to receive standard of care chemotherapy".
If not, why set it up this way now?
Why not MT-601 as a stand alone treatment?
Do they even know how chemotherapy will affect MT-601 efficiency? good or bad?
Will the side affects of chemotherapy now going to tacked on as side affects of MT-601?
Phantom, I read the following at stocktwits: "As of September 15, 2022, the Company and its landlord agreed to terminate the Company’s office lease at 3200 Southwest Freeway, Suite 2500, Houston, Texas. As such the Company reduced its operating lease liabilities by $3.7 million and reduced its right-of-use
assets by $3.5 million".
I thought they were at 4551 Kennedy Commerce Drive, Houston, TX 77032.
R+D at 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
What's the deal with 3200 Southwest Freeway? and what does it mean in the big picture?
Thank You
"The Company expects to announce an efficacy analysis from the six patients in Cohorts 4 and 5 by year-end."
Yeah Sure they will, I'll believe it when I see it.
Other than that, I see NOTHING NEW.
I read that this morning, MACK is eligible for up to $450 million in contingent milestone payments. They sold the drug 5 years ago. MACK is up 200% today. Thanks
Down pretty big. I guess people were expecting some kind of news yesterday.
Thanks for all the info
Question for Phantom (and also opinions of others): Even if good data news comes out before end of year and even if MRKR can get share price above $1 before end of year ... wouldn't we be better off "In The Long Run" if we do a reverse split anyway?
If they do a 1 for 20 RS, we go from having 84 million shares to just 4 million shares, and wouldn't having 4 mil instead of 84 mil make it alot harder for short sellers to short in the future (which we KNOW they will again as soon as MRKR reports good data news and thus the share price goes up), just simply because they would be 20 times less shares available to short?
No share holder will lose a single penny if they do a RS as the value of your shares after the RS is the exact same value of your shares before the RS.
.
And also, wouldn't having a 20 times higher share price make it easier to do a cash raise dilution if that is needed in the future?
And, wouldn't having a 20 times higher share price make it easier and more likely that Mutual funds would be able to (by their bylaws) add MRKR to their portfolio?
Thanks to you and all in advance.
If I read that correctly, it all has to do with the legacy TPIV vaccine candidates which are all history as far as trials and MRKR.
Unless I am wrong, I don't think we lose any money or make any money.
Is that correct?
I don't want a merger until we have a market cap of like 500 million. The only reason for a merger then, AFTER the science proves itself would be for the ability to immediately jump in full blast and start 10 new trials for many cancer indications using the buyers money.
Until then do it alone. If we have to do a reverse split, fine, do it by our selves. If we have to do a dilution, fine, do it by our selves. If the science is correct, the big profits are out there. They may be down the road a bit, but to get bought out crazy cheap and give our profits to the buyer would be nothing but a wasted and missed opportunity. We have worked too hard for too long and invested in our faith for too long to give it all away in desperation.
Do it alone until the science proves itself and pays off ... or die alone trying.
I don't want to belabor the point, but I have been thinking about this "worth" subject and it seems to me that there is an unfairness, a nonrecognition componant, and a need for a kickback system in this whole "worth" issue.
Hypothetically, let's just say that Marker or someone else comes up with a cure for 2 or 3 or 4 types of cancer.
Everyone chants Yeah Great, the combined cancer market for those "cures" is 5 billion, Marker or another gets half the market, Yeah Great, there are worth 2.5 billion.
What's unfair about that?
What componant is not being recognized?
Who should be giving kickbacks?
How many BILLIONS of dollars will be saved because of not having to spend them by Medicaid and Medicare and private insurance companies for non-needed treatments? Which is a savings for all American citizens.
How many Hundreds of Millions of dollars will be saved by insurance companies who no longer are paying death benefits to cancer survivors (yet), who will now be able to continue to collect premiums for many more years and decades?
I know, blah blah blah, none of this concerns or is factored into a companies market cap.
There just seems to be an unequity aspect that will never be rewarded that just doesn't sit right with me.
Howdy Phantom, I took your lead and looked up the market for Pancreatic cancer.
2.6 billion going to 3.7 billion.
https://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market
Still can't wrap my head around how a CANCER cure could be worth so much less than 100 other things that don't kill you.
But it is what it is.
"The psoriasis market was ~$27B this year and expected to rise to ~$51B by 2030 (SOURCE) while the AML market was ~$1B this year and expected to rise to ~$2.5B in 2030 (SOURCE)."
"the market for psoriasis is 20x the AML market "
WOW, I had NO IDEA that was the case and the facts.
My feeble mind just said that a cure for cancer has to be worth a ton more money that a cure for an itchy scalp.
I know "itchy scalp" is an oversimplification of psoriasis.
Once again, Thanks for your reply and stating the facts.
I guess, along with everybody else, I will just sit and wait for data.
Thanks Again.
Just a silly question as we wait for results. If in 2023 we get very postive results for the adjuvant group for AML ........... if a phase one study for Psoriasis is somehow worth 3 Billion ....... what should MRKR jump up to on positive AML news?
5 Billion? 10 Billion? 20 Billion?
People will say, oh MRKR can triple or quadruple .... to what, 75 Million or 100 Million?
That is STILL total BS. If phase one Psoriasis trial is worth 3 billion, an AML cure should be at least 10 times that. I know a jump to 30 billion ain't going to happen, but the disjointed, out of touch anti-reality of these market caps are just sickening.
I wrote a post like this a couple of years ago, just to show the absolutely ridiculousness of both MRKR share price and also analysts ratings.
Just over the last couple of weeks, a few small biotechs took off.
One of them DICE, has ONE clinical trial going on and it is a Phase ONE trial for Psoriasis. THAT'S IT, one trial for Psoriasis. Now yes, Psoriasis needs to be treated but it is NOT as bad as dying of cancer that MRKR is trying to cure.
DICE market cap, pushing TWO BILLION, currently at $42 a share and analysts are raising price targets to $60 and $77.
WHY?? for ONE Phase ONE trial for Psoriasis. Again, WTF and WHY.
Their ONLY pipeline trial is a phase one for Psoriasis. DICE 2 Billion, MRKR 25 Million.
I can type for hours with other examples but they all lead back to the same questions.
Are these analysts stupid or blind or getting paid off or their firms getting paid off or WHAT?
PLEASE TELL ME how analysts can say a biotech with ONE PHASE ONE trial for Psoriasis has a price target of THREE BILLION ....... when MRKR trying to cure cancer and has PROVEN track record of NO NONE NO cytokine release syndrome .... PROVEN track record of epitope spreading ...... PROVEN track record of positve results with NO patient deaths, and MRKR is only worth 25 million.
I am sorry but it just makes me want to scream WTF is going on in this bizarre biotech universe.
I think the main problem is that management is focusing on the company, the science, and communicating with the large institutional investors, as they should be, but are totally inept in their negligence and dismissal of us small investors, like they don't even care about us or like we don't even exist to them.
MRKR says data in Q3, then says oops we made a mistake, we meant Q4,
then MRKR goes down 20+%.
GOOD JOB MANAGEMENT! WAY TO INSTILL CONFIDENCE!
and BTW ... AS EXPECTED ... NO answers to any of my emails to anybody.
Thanks Again.
Thank You, looking forward to any info your further post.
I honestly don't think any of us will be getting an email answer back from anyone .......... SAD TO SAY.
That would be nice, the only problem I see is that any near term results will only be for the "active" group (the sickest and worse off patients), so I don't see very much really great news on that front. We need the great results with the adjuvant patients, but that data is a ways off.
I still think something along the lines of what I posted on May 27 (post 32102) is going to happen:
"This is all setting up great:
First, do a reverse split, after which THAT stock price will continue to slowly drift downward.
Second, do a dilution offering at an even LOWER price, which will, of course cause the stock price to go down even further.
Third, invest" ... more $'s ... hopefully ... "RIGHT BEFORE they announce great trial data for adjuvant AML and Pancreatic."
I will post whether I get a response to my emails or not.
Just sent them all the following:
Hello, I've been with MRKR since early TPIV, am down about 150K.
Taking into consideration the following:
November 10, 2021: Q3 2021 Update PR
“Topline readout of Group 2 active disease anticipated in Q1 2022"
March 17, 2022: YE 2021 Update PR
“Topline readout of Group 2 active disease anticipated in Q2 2022”
May 13, 2022: Q1 2022 Update PR
“Topline readout of Group 2 active disease is anticipated in Q2 2022”
August 11, 2022: Q2 2022 Update PR
“We expect to provide a topline readout of active disease patients in Q3 2022”
And since not a single time was any explanation given as to why the data date was missed, do you have any kind of accurate estimate of when Topline readout of Group 2 active disease will actually be released?
Thank You
"they have not instilled a lot of confidence with this"
"this is just poor business practice no matter how you look at it"
I COULDN'T AGREE MORE.
YEAH, I kind of did that with you in mind because you mentioned Woodstock.
For anyone who remembers Country Joe and the Fish:
And it's 1 - 2 - 3 what are we hoping for
Don't ask me cause I don't know
I just hope we don't go down to zero
And it's 5 - 6 - 7 all we can do is wait
But it sure is making my nerves agitate
Come on Wall Street don't be slow
Please make Marker Go Go Go
There's plenty good money to be made
If on great news we start to trade
Don't be caught sleeping and hesitate
Buy Marker stock before it's too late
You can be the first ones in your block
To say that Marker was not a crock
So buy it now and don't be rash
Whoopee! we're all gonna cash
The greatest band of all time and the lyrics tell MRKR's story:
When I was a child ..............................(many years ago)
I caught a fleeting glimpse ..................(of Markers potential)
Out of the corner of my eye ................(I was sure I saw it)
I turned to look but it was gone ...........(along with the stock price and our money)
I cannot put my finger on it now ..........(except to keep hitting the BUY button)
The child is grown ...............................(but obviously not much wiser)
The dream is gone ..............................(NO, I still hold out hope)
I have become comfortably numb .......(with good aged Tawny Port)
Not sure how this will effect MRKR, as they were talking specifically about beast cancer:
"So, our team is partnering with the National Breast Cancer Coalition and the National Cancer Institute to develop a primary prevention vaccine for breast cancer. We're not just talking about triple negative breast cancer, we're talking about all of the breast cancers, the 260,000 cases per year that was initially brought up as the number of cases in the U.S. that we have every year with breast cancer."
You've heard of the gift that keeps giving and giving ... now we have the stock that keeps taking and taking.
And YES, like an idiot, I will buy more when it gets under 20 cents.
Just stubborn I guess ... or stupid ... or both.
Blah Blah Blah = nothing nothing nothing new.
It is going to cost us $700,000 to get rid of ANTHONY H. KIM the CHIEF FINANCIAL OFFICER.
"Marker is on track to file an IND for MT-601 for the treatment of pancreatic cancer in 2022."
TIMBER .... don't try to catch a falling knife ..... until the knife gets down to about ......
UNDER 20 CENTS.
It will come, either due to reverse split or dillution or most likely BOTH.
OK, hurry up and wait ...... and then wait some more.
I still think there is a "lack of awareness" problem concerning MRKR and Multi TAA therapy.
I understand what Phantom said about CAR-T being the "approved" therapy, but I wish more Doctors and patients were more aware of Multi TAA so that they would .... under both what is called "compassionate care" drug use or the newer "right to try" law, TRY MRKR's Multi TAA therapy.
GEEZ, can you imagine if Alex Trebek would have tried Multi TAA and been cured of his pancreatic cancer?
The word would be out then.